Ultime notizie per VIZIO Holding (NYSE:VZIO) Azioni

VIZIO Holding

VIZIO Holding Corp operates two distinct integrated businesses: Device and Platform+. Through Device business, it offers a range of high-performance Smart TVs designed to address specific consumer preferences, as well as a portfolio of soundbars that deliver immersive audio experiences. It generates revenue from the shipment of these devices to retailers and distributors across the United States, as well as directly to consumers through the website. The Company's reportable segments: Device, and Platform+T. It derives maximum revenue from Device Segment.

VIZIO Holding Corp

Oppenheimer analyst Jed Kelly upgrades Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from Perform to Outperform and announces $6 price target.

News

Upgrades

Price Target

Analyst Ratings

SGHC

Oppenheimer Upgrades Super Group (SGHC) to Outperform, Announces $6 Price Target

Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.50) by 30 percent. This is a 94.44 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $16.352 million which beat the analyst consensus estimate of $12.609 million by 29.69 percent.

Earnings

Earnings Beats

PHAT

Phathom Pharmaceuticals Q3 2024 Adj. EPS $(1.05) Beats $(1.50) Estimate, Sales $16.352M Beat $12.609M Estimate

2024 Financial Guidance
<ul>
<li>Maintained total net revenue guidance of $238 to $242 million, or 20% to 23% growth</li>
<li>Profitability guidance raised to 72% gross margin and 22% adjusted EBITDA margin, compared to the previous guidance of 71% and 21%, respectively</li>
</ul>

Guidance

VCEL

Vericel Affirms FY24 Sales Guidance Of $238.00M-$242.00M Vs. $240.02M Estimate

General

LiveOne's Paid Members As Of September 30, 2024 Increased 645K Or 27%, As Compared To The Prior Year. Total Members Including Free Ad-supported Memberships Was Approximately 4M

Wheels Up Experience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) reported quarterly losses of $(0.08) per share. The company reported $193.90 million in sales this quarter. This is a 39.42 percent decrease over sales of $320.06 million the same period last year.

Wheels Up Experience Q3 EPS $(0.08) Up From $(3.15) YoY, Sales $193.90M Down From $320.06M YoY

Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Tex.
The data presented demonstrated that Decoy20 administered intravenously once weekly mainly showed side effects that were classified as mild or moderate and transient in duration. Further, pharmacokinetic analysis confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's "pulse" approach. One patient in the trial who has squamous cell carcinoma of the head and neck (SCCHN) with high levels of PD-L1, which is a protein that is associated with tumor response to certain immunotherapies, had "stable disease" — meaning the cancer had not progressed or worsened — at the time of their first imaging scan.

Biotech

INDP

Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial Of Decoy20 At The Society For Immunotherapy Of Cancer 2024 Annual Meeting

WIIM

Texas Pacific Land shares are trading lower after the company reported a year-over-year decrease in Q3 EPS results and worse-than-expected Q3 sales results.

HC Wainwright &amp; Co. analyst Ed Arce reiterates Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) with a Buy and maintains $75 price target.

Reiteration

ALGS

HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $75 Price Target

Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) reported quarterly earnings of $2.54 per share which beat the analyst consensus estimate of $2.41 by 5.39 percent. The company reported quarterly sales of $1.726 billion which beat the analyst consensus estimate of $1.677 billion by 2.90 percent. This is a 5.70 percent increase over sales of $1.633 billion the same period last year.

Ralph Lauren Q2 2025 Adj. EPS $2.54 Beats $2.41 Estimate, Sales $1.726B Beat $1.677B Estimate

LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $32.59 million which missed the analyst consensus estimate of $33.70 million by 3.28 percent. This is a 14.25 percent increase over sales of $28.53 million the same period last year.

LiveOne Q2 2025 GAAP EPS $(0.02) Misses $(0.01) Estimate, Sales $32.59M Miss $33.70M Estimate

IHRT

iHeartMedia Q3 Sales $1.008B Beat $1.001B Estimate

Nano is Successfully Executing a Disciplined and Focused Value Creation Strategy to Drive Value for ALL Shareholders
Murchinson's Self-Serving Campaign is an Attempt to Take Control of Nano Through a Series of Proposals that Would Paralyze the Company's Strategy
Nano Urges Shareholders to Protect Their Investment and Vote "FOR" Nano's Proposals
Act Fast – Voting Cut-Off Sunday, December 1st, 2024, at 11:59 p.m. ET
To Learn More Visit: <a href="https://www.globenewswire.com/Tracker?data=gzWXWYPEmuxT_FDF7tP29TzULnkhGWfeFdtoFYVhazjDslpMj0ldHB5pPuUy0Z_Pefk22Phd7D3wBn129zu384B-e_DkBLlWduMae9P97tunW6AyM6YxQYY-NFv0tklJ">www.ProtectingNanoValue.com</a>
Waltham, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>) ("Nano" or the "Company"), a leading supplier of Additively Manufactured Electronics ("AME") and multi-dimensional polymer, metal &amp; ceramic Additive Manufacturing ("AM") 3D printing solutions, today sent a letter to its shareholders in connection with the Company's upcoming 2024 Annual General Meeting of Shareholders ("the Annual Meeting"). The letter reiterates the disciplined and focused steps the Company is taking to drive value for all shareholders.
&nbsp;

NNDM

Nano Dimension Sends Letter to Shareholders; Says Murchinson's Self-Serving Campaign Is An Attempt To Take Control Of Nano Through A Series Of Proposals That Would Paralyze The Company's Strategy; Nano Urges Shareholders To Protect Their Investment And Vote "FOR" Its Proposals

Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.20 by 20 percent. The company reported quarterly sales of $225.827 million which missed the analyst consensus estimate of $247.230 million by 8.66 percent. This is a 26.34 percent decrease over sales of $306.576 million the same period last year.

Earnings Misses

Medical Properties Trust Q3 2024 FFO $0.16 Misses $0.20 Estimate, Sales $225.827M Miss $247.230M Estimate

Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 75 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $57.901 million which beat the analyst consensus estimate of $55.201 million by 4.89 percent. This is a 27.03 percent increase over sales of $45.581 million the same period last year.

Vericel Q3 2024 GAAP EPS $(0.02) Beats $(0.05) Estimate, Sales $57.901M Beat $55.201M Estimate

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $28 price target.

ACAD

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target

Chicago Atlantic Admin acted as administrative agent on the funding of a $30 million senior secured credit facility for Deep Roots Holdings, a vertically integrated cannabis operator in Nevada. Deep Roots Holdings has a standalone cultivation and processing facility in the Silver State, runs five dispensaries and plans to open one more in Dec. 2024.
"Deep Roots is a company to watch in 2025, and it's our pleasure to take a front-row seat and support their growing investment portfolio," stated David Kite, managing partner at Chicago Atlantic. "Their team has shown operational expertise at every level, exceptional business acumen and a strong balance sheet – We couldn't be more excited to partner with them."
The capital provided by Chicago Atlantic, on behalf of its affiliated investment funds, will support Deep Roots Harvest's expansion as it takes on additional retail and cultivation assets across Nevada. In October 2024, Deep Roots Harvest <a href="https://www.benzinga.com/markets/cannabis/24/04/38450434/deep-roots-harvest-to-acquire-the-source-operation-in-nevada">acquired most of the asset</a>s of Nevada cannabis operator The Source Holdings, LLC, including four retail operations, two provisional retail licenses and one operating facility for cultivation.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41765421/south-dakota-rejects-measure-29-cannabis-legalization-fails-again">South Dakota Rejects Measure 29: Cannabis Legalization Fails Again</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
The successful move positions Deep Roots to operate 12 total dispensaries and establishes them as the market share leader in Nevada.
Keith Capurro, CEO of Deep Roots Harvest, said the company will continue its strategic growth in 2025 and beyond.
"Chicago Atlantic has quickly proven themselves as a valuable partner as we continue to invest across our portfolio of businesses," said Capurro. "With a larger balance sheet and meaningful additional borrowing capacity, we are well positioned to execute on our broader strategy."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/07/33098371/chicago-firm-sees-value-in-ny-rec-market-speeds-up-roll-out-with-150m-investment">Chicago Firm Sees Value In NY Rec Market, Speeds Up Roll-Out With $150M Investment</a></li>
</ul>
Photo: Courtesy of Deep Roots Harvest via Business Wire

Cannabis

Cannabis Operator Deep Roots Harvest Secures $30M From Chicago Atlantic To Expand Across Nevada

Health Care

ADPT

Adaptive Biotechnologies Announced That Palmetto GBA, A Medicare Administrative Contractor, Has Expanded Coverage Of clonoSEQ To Include Detection And Monitoring Of Measurable Residual Disease In Medicare Patients With Mantle Cell Lymphoma

NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.0, a high estimate of $37.00, and a low estimate of $31.00. This current average reflects an increase of 0.95% from the previous average price target of $34.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984473_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive NewAmsterdam Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NewAmsterdam Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NewAmsterdam Pharma compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of NewAmsterdam Pharma's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NewAmsterdam Pharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NAMS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NewAmsterdam Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into NewAmsterdam Pharma's Background</h2>
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
<h3>Financial Milestones: NewAmsterdam Pharma's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: NewAmsterdam Pharma displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 32.73%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1711.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): NewAmsterdam Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.76%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NewAmsterdam Pharma's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.34%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NewAmsterdam Pharma's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NAMS

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma

Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high estimate of $70.00, and a low estimate of $55.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984463_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Ionis Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ionis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Ionis Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ionis Pharmaceuticals analyst ratings.</a>
<h2>About Ionis Pharmaceuticals</h2>
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
<h3>Key Indicators: Ionis Pharmaceuticals's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ionis Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 19.55%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ionis Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -29.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -23.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 5.47. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IONS

Where Ionis Pharmaceuticals Stands With Analysts

5 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.4, a high estimate of $20.00, and a low estimate of $15.00. This current average has increased by 0.87% from the previous average price target of $17.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984454_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Amicus Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dennis Ding</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Amicus Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Amicus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amicus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Discovering Amicus Therapeutics: A Closer Look</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Financial Insights: Amicus Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Amicus Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 34.04% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Amicus Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -12.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Amicus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -11.93%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Amicus Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Amicus Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 3.35. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FOLD

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights

The Trade Desk is working on its own smart TV OS: report

Spotlight On Jobs Report, U.S. Auto Sales, Dollar Store Drama, And Citi TMT Conference

Wall Street Breakfast: The Week Ahead

Vizio ticks higher amid report Walmart targeting mid-November close

Analysts have been eager to weigh in on the Technology sector with new ratings on Zeta Global Holdings Corp (ZETA – Research Report) and VIZIO Hold...

Analysts' Opinions Are Mixed on These Technology Stocks: Zeta Global Holdings Corp (ZETA) and VIZIO Holding (VZIO)

Vizio falls amid Capri deal block; new short idea at Hedgeye

Vizio gains after report Walmart deal may close late this month, early December

Vizio GAAP EPS of $0.00 beats by $0.02, revenue of $444.7M beats by $0.9M

Reports Q3 revenue $444.7M, consensus $443.8M. SmartCast Average Revenue Per User of $37.17 was up 18% y/y. Published first on TheFly – the ultimat...

Vizio reports Q3 EPS 0c, consensus (2c)

Vizio Holding Corp. ( ($VZIO) ) has released its Q3 earnings. Here is a breakdown of the information Vizio Holding Corp. presented to its investors...

Vizio Holding Corp. Reports Q3 2024 Financial Growth

AMZN

AVGO

BSLK

CASY

CGBS

CHPT

CHTR

CMCSA

CPRI

DLTR

DOCU

GOEV

GOOG

GOOGL

GTHX

GTLB

INTC

KRUS

LGCL

PMAX

RAIL

RENT

ROKU

RRGB

SSNLF

TERN

VICI

VRCA

VZIO

ZETA

Press Releases

New VIZIO Sports Zone Simplifies Game Discovery

VIZIO Expands Popular WatchFree+ Service to VIZIO Mobile App

KERV Interactive Partners with VIZIO for Interactive CTV Ad Experiences

VIZIO's QuickFit Solution Elevates Home Entertainment Setup

Stingray Brings the Ultimate Karaoke Experience to VIZIO

VIZIO Announces Exclusive Series 'Rockstar Kitchen Chronicles' Hosted by Gavin Rossdale at Advertising Week 2024

Comments

VIZIO Holding

Notizie

Ultime notizie per VIZIO Holding (NYSE:VZIO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO